Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870801 | 1.00 | CHRM3 (0.41) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL21003218 | 0.98 | CHRM3 (0.44) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL322784 | 0.86 | CHRM3 (0.45) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL21003185 | 0.83 | CHRM3 (0.47) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL21003184 | 0.83 | CHRM3 (0.36) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL21003236 | 0.81 | CHRM3 (0.49) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL18756130 | 0.80 | CHRM3 (0.49) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL21003216 | 0.80 | CHRM2 (0.50) | CHRM3HTR2CCHRM2CHRM4CHRM5 | |
| SCHEMBL21002844 | 0.79 | KDR (0.36) | CHRM3HTR2CKDRKCNH2SIGMAR1 | |
| SCHEMBL25678467 | 0.78 | CYP1A2 (0.36) | HTR2CKDRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0877734-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997023462-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | CHRM3 15/4885HTR2C 698/4885CHRM2 38/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | CHRM3 16/4885HTR2C 750/4885CHRM2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.